SOURCE: Cavit Sciences, Inc.

June 14, 2007 08:00 ET

Cavit Sciences, Inc. Announces Testing Results of Drug for Cancer and Viral Infection Treatment

DELRAY BEACH, FL--(Marketwire - June 14, 2007) - Cavit Sciences, Inc. ("Cavit") (OTCBB: CVIT) today announced information regarding a drug in development and results of testing performed on the drug.

We are pleased to announce the Company's lead product candidate, CT-5. In Japan, Maruyama vaccine (SSM) has been used for over 25 years as a cancer treatment with proven results. A diluted form of SSM has been safely administered to humans in the U.S. and overseas with minimal side effects. For testing and clinical trial purposes, the development code and generic name of Cavit's drug is CT-5, which corresponds to the diluted form of SSM that has achieved the testing results listed below.

The testing conducted in the U.S. and overseas included testing in vitro, on animals and on humans and has demonstrated promising results. The following indications have been shown, suggested or proven by the use of diluted SSM alone or in conjunction with other therapies and/or other substances.

IN VITRO TESTING:

1) Inhibits HIV-1 virus replication.

ANIMAL TESTING:

2) Inhibits metastasis of melanoma and suppression of tumor metastasis.
3) Survival rates of subjects infected with leukemia virus were
   significantly increased.
4) Displays potent activity against tumor growth.

HUMAN TESTING: (in conjunction with other therapies and/or other
                substances)

5) Progression-free survival of humans was significantly improved in
   patients with advanced cervical cancer showing a 30% reduction in the
   death rate.
6) Acts by inducing encapsulation of tumor growths, possibly preventing
   their spread and metastasis.
7) May benefit patients in whom tumor is inoperable and resistant to
   conventional chemotherapy.
8) HIV-1 infected patients participating in a trial showed that the drug
   was well tolerated and the trial demonstrated its safety.
9) The optimal dose of the drug was determined in a study of patients with
   stage IIIB cervical cancer.
Because of SSM's long history of use in Japan, there has been extensive scientific data, publications and testing results relating to SSM and its diluted form publicly available. Cavit believes that aggressive development of CT-5 is clearly merited. This approach provides us with risk-reducing data on the safety and efficacy of CT-5 in the treatment of patients sooner than would have been possible under a more traditional pathway. Diluted SSM has been approved in Japan since 1991 for the treatment of radiotherapy-induced leukopenia and is currently undergoing Phase 3 clinical trials on behalf of a pharmaceutical company in Japan for the treatment of cervical cancer.

Cavit's researchers have been working with scientists and researchers that performed testing on diluted SSM, in order to finalize testing and seek approval for this drug in the treatment of cancers, viral infections and related diseases. Cavit's team is aggressively moving our current intellectual property rights forward with CT-5's advancement in order to develop it quickly and cost-effectively. We are working towards the goal of having this drug available to patients and individuals for the prevention and treatment of diseases in the U.S. and worldwide.

Cavit Sciences, Inc. ("Cavit") is a biotechnology company engaged in developing treatments and prevention for cancer and viral infections. Additional information is available on the Company's soon to be updated website at: www.cavitsciences.com

Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. Cavit's drug has not been evaluated by the Food and Drug Administration and the efficacy of this drug has not been confirmed by FDA-approved research. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Cavit. These factors include, but are not limited to: (i) the ability of Cavit to successfully raise financing, (ii) the ability of Cavit to finalize its manufacturing and distribution facilities, and (iii) the ability of Cavit to successfully commercialize its products in certain markets. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Cavit's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" for Cavit on Form 10K-SB filed on April 12, 2007.

Contact Information